China's biotech boom doubles lab monkey prices as drug pipeline outpaces primate supply

China's lab monkey shortage is pushing prices toward $26K per animal

Lab monkey prices in China have doubled in the past year, with a state laboratory paying roughly $26,000 per animal for a batch of 40 monkeys in June—nearly double what similar animals cost a year earlier. The surge reflects a critical supply-demand imbalance in the country's drug development ecosystem.

The driver is straightforward: China's biotech industry is generating a third of the global pipeline of novel medicines, and many of these experimental drugs—particularly biologics and next-generation therapies—require primate testing before regulators allow human trials. Demand for preclinical testing has accelerated far faster than breeding capacity can supply.

Regulated monkey farms have maintained relatively steady production. The bottleneck is real. Many experimental medicines cannot advance without nonhuman primate studies, and monkeys remain one of the best available models because their biology closely resembles humans. They're essential for evaluating drug safety, how treatments move through the body, and effects on organs before human trials begin.

This is not the first time the market has felt the strain. A similar price spike occurred during COVID-19 vaccine development. This time, the pressure reflects China's emergence as a major center for innovative drug discovery—and a destination for clinical trials and licensing deals with U.S. and European pharmaceutical companies.

The shortage could slow some research programs, but it's also a symptom of unprecedented investment in drug development aimed at producing potentially life-saving treatments.